Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969583 | 0.97 | PTPRC (0.47) | PTPRCMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL5351912 | 0.94 | ALDH1A1 (0.47) | PTPRCTSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL28693655 | 0.89 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10ALDH1A1MAPT | |
| SCHEMBL30731584 | 0.87 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10ALDH1A1MAPT | |
| SCHEMBL23969638 | 0.87 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10ALDH1A1MAPT | |
| SCHEMBL1537373 | 0.86 | ALDH1A1 (0.48) | MEN1KMT2AHSD17B10ALDH1A1MAPT | |
| SCHEMBL31121819 | 0.86 | ALDH1A1 (0.46) | TSHRMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL16142399 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3676598 | 0.84 | ASAH1 (0.48) | MEN1KMT2AHSD17B10ALDH1A1MAPT | |
| SCHEMBL28775914 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20070238781-A1 | Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex | EIGENBRODT ERICH | 2007-10-11 | — | — | US | disclosed |
| US-7223784-B2 | Compounds for the modulation of the glycolysis enzyme and/or transaminase complex | ScheBo® Biotech AG (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238781-A1 | Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex | PC, GOT1, PCK1 | PTPRC 1578/4885TSHR 3366/4885MEN1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.